MA49133A - Anticorps agonistes anti-btla et leurs utilisations - Google Patents

Anticorps agonistes anti-btla et leurs utilisations

Info

Publication number
MA49133A
MA49133A MA049133A MA49133A MA49133A MA 49133 A MA49133 A MA 49133A MA 049133 A MA049133 A MA 049133A MA 49133 A MA49133 A MA 49133A MA 49133 A MA49133 A MA 49133A
Authority
MA
Morocco
Prior art keywords
agonist antibodies
btla agonist
btla
antibodies
agonist
Prior art date
Application number
MA049133A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Victor H Obungu
Andrew Charles Vendel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA49133A publication Critical patent/MA49133A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049133A 2017-05-19 2018-05-11 Anticorps agonistes anti-btla et leurs utilisations MA49133A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
MA49133A true MA49133A (fr) 2020-03-25

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049133A MA49133A (fr) 2017-05-19 2018-05-11 Anticorps agonistes anti-btla et leurs utilisations

Country Status (25)

Country Link
US (2) US10604573B2 (fr)
EP (1) EP3625257A1 (fr)
JP (2) JP6790304B2 (fr)
KR (3) KR102294051B1 (fr)
CN (3) CN117402245A (fr)
AR (1) AR111752A1 (fr)
AU (2) AU2018269585B2 (fr)
BR (1) BR112019021547A2 (fr)
CA (2) CA3184628A1 (fr)
CL (1) CL2019003215A1 (fr)
CO (1) CO2019012756A2 (fr)
CR (1) CR20190521A (fr)
DO (1) DOP2019000293A (fr)
EA (1) EA201992460A1 (fr)
EC (1) ECSP19082184A (fr)
JO (1) JOP20190261A1 (fr)
MA (1) MA49133A (fr)
MX (1) MX2019013604A (fr)
MY (1) MY197425A (fr)
NZ (1) NZ758360A (fr)
PE (1) PE20191843A1 (fr)
PH (1) PH12019502575A1 (fr)
TW (4) TWI677504B (fr)
WO (1) WO2018213113A1 (fr)
ZA (1) ZA201906954B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
WO2023143565A1 (fr) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anticorps anti-btla et leurs utilisations dans le traitement du cancer
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (fr) * 2002-10-25 2016-04-20 Genentech, Inc. Nouvelle composition et procedes pour le traitement de maladies auto-immunes
AR063840A1 (es) * 2006-11-15 2009-02-25 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso
AR077594A1 (es) 2009-07-31 2011-09-07 Organon Nv Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (fr) * 2012-07-26 2014-01-30 The General Hospital Corporation Méthodes et compositions pour le traitement d'une maladie auto-immune
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
US11352428B2 (en) * 2015-04-29 2022-06-07 Sanford Burnham Prebys Medical Discovery Institute Modulation of immune response using BTLA agonist antibodies
WO2017096017A1 (fr) * 2015-12-02 2017-06-08 Stsciences, Inc. Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)

Also Published As

Publication number Publication date
KR102294051B1 (ko) 2021-08-27
CA3064518A1 (fr) 2018-11-22
AU2021277743A1 (en) 2021-12-23
AR111752A1 (es) 2019-08-14
JP2021019642A (ja) 2021-02-18
TW201904991A (zh) 2019-02-01
CO2019012756A2 (es) 2020-01-17
AU2018269585B2 (en) 2021-09-02
JOP20190261A1 (ar) 2019-11-05
MX2019013604A (es) 2019-12-18
PE20191843A1 (es) 2019-12-31
KR20190140969A (ko) 2019-12-20
KR20210106033A (ko) 2021-08-27
CN110621699A (zh) 2019-12-27
JP6790304B2 (ja) 2020-11-25
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
NZ758360A (en) 2022-10-28
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
ZA201906954B (en) 2021-06-30
TW202233681A (zh) 2022-09-01
CR20190521A (es) 2020-01-06
CA3184628A1 (fr) 2018-11-22
WO2018213113A1 (fr) 2018-11-22
US10604573B2 (en) 2020-03-31
US20180334502A1 (en) 2018-11-22
CN117402244A (zh) 2024-01-16
ECSP19082184A (es) 2019-11-30
CL2019003215A1 (es) 2020-04-13
EA201992460A1 (ru) 2020-03-18
CN117402245A (zh) 2024-01-16
KR20220158847A (ko) 2022-12-01
MY197425A (en) 2023-06-16
US11396545B2 (en) 2022-07-26
TWI804044B (zh) 2023-06-01
TW202334237A (zh) 2023-09-01
US20200239578A1 (en) 2020-07-30
TWI747043B (zh) 2021-11-21
JP2020518288A (ja) 2020-06-25
AU2018269585A1 (en) 2019-10-31
TWI677504B (zh) 2019-11-21
PH12019502575A1 (en) 2020-07-13
EP3625257A1 (fr) 2020-03-25
BR112019021547A2 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA47694A (fr) Anticorps anti-tigit
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49034A (fr) Anticorps anti-lag3
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA47268A (fr) Anticorps anti-gpc3
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations